Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7126209 multiple ascending dose study in prodromal or mild to moderate Alzheimer's disease
jRCT2051230101Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing RO7126209 with Placebo (2 arms). Primary endpoints: Percentage of participants with adverse events and Change from baseline in brain amyloid load by amyloid PET. Started Oct 2023; status: active, not recruiting.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2051230101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230101.